Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

By sjmartinez • December 13, 2024

Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton KE, Domin E, Lin BC, McKee K, Doria-Rose N, Regenold S, Spiegel H, Anderson M, McClosky N, Zhang L, Piwowar-Manning E, Ackerman ME, Pensiero M, Dye BJ, Landovitz RJ, Mayer K, Siegel M, Sobieszczyk M, Walsh SR, Gama L, Barouch DH, Montefiori DC, Tomaras GD; HVTN 136/HPTN 092 Study Team. Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial. Lancet HIV. 2024 Dec 9:S2352-3018(24)00247-9. doi: 10.1016/S2352-3018(24)00247-9. Epub ahead of print. PMID: 39667379.

Tags: Infectious Diseases, Publications

The transcription factor Ahr1 governs the recruitment of neutrophils to the brain and clearance of Candida albicans during CNS infection

Wakade RS, Solis NV, Ristow LC, Wellington M, Filler SG, Krysan DJ. The transcription factor Ahr1 governs the recruitment of neutrophils to the brain and[...]

Olorofim in Treatment of Patients With Poorly Controlled Disseminated Coccidioidomycosis : A Single-Group, Open-Label, Phase 2b, Multicenter Study

Donovan FM, Johnson RH, Patterson TF, Hoenigl M, Spec A, Sikka MK, Holland SM, Shoham S, Schaenman JM, Mehta SR, Kuran RA, Galgiani JN, Bresnik[...]

The hantavirus question we are not asking

Hensley LE, Halbrook M, Hoff NA, Merritt S, Olinger GG, Skinner B, von Fricken ME, Kindrachuk J, Rimoin AW. The hantavirus question we are not[...]